A qualitative analysis to identify implementation strategies for a deprescribing clinical practice guideline using the CFIR-ERIC Matching Tool: perspectives from consumers and professional stakeholders.

IF 3.2 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Hui Wen Quek, Xisco Reus, Kenneth Lee, Veronika Seda, Leon Adams, Osvaldo P Almeida, Gillian E Caughey, Jennifer Gowan, Kerryn Hart, Andrew Heredia, Anne-Marie Hill, Lisa Kalisch Ellett, Dina LoGiudice, Arduino A Mangoni, Anthony Marinucci, Treasure McGuire, Nilufeur McKay, Vasi Naganathan, Christopher Ng, Maz Osborne, Kevan R Polkinghorne, Constance D Pond, Sepehr Shakib, Angela Shiu, Andrew Stafford, Tim Whitmore, Christopher Etherton-Beer, Amy Page
{"title":"A qualitative analysis to identify implementation strategies for a deprescribing clinical practice guideline using the CFIR-ERIC Matching Tool: perspectives from consumers and professional stakeholders.","authors":"Hui Wen Quek, Xisco Reus, Kenneth Lee, Veronika Seda, Leon Adams, Osvaldo P Almeida, Gillian E Caughey, Jennifer Gowan, Kerryn Hart, Andrew Heredia, Anne-Marie Hill, Lisa Kalisch Ellett, Dina LoGiudice, Arduino A Mangoni, Anthony Marinucci, Treasure McGuire, Nilufeur McKay, Vasi Naganathan, Christopher Ng, Maz Osborne, Kevan R Polkinghorne, Constance D Pond, Sepehr Shakib, Angela Shiu, Andrew Stafford, Tim Whitmore, Christopher Etherton-Beer, Amy Page","doi":"10.1007/s11096-026-02218-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Deprescribing is the planned withdrawal or dose reduction of medicines when harms outweigh benefits or when they are no longer required. Following publication of the Clinical Practice Guideline for Deprescribing in Older People in September 2025, supporting its uptake into routine practice is a critical next step.</p><p><strong>Aim: </strong>This study aimed to identify implementation strategies, informed by stakeholder-perceived barriers, to support the implementation of deprescribing guidelines.</p><p><strong>Method: </strong>A qualitative analysis was undertaken of open-text responses collected during the guideline public consultation (24 April-31 May 2025). Inductive thematic analysis identified implementation barriers, which were then deductively mapped to the Consolidated Framework for Implementation Research (CFIR). Relevant CFIR constructs were entered into the CFIR-Expert Recommendations for Implementing Change (ERIC) Matching Tool to generate implementation strategies. Strategies were ranked by cumulative percentage endorsement and grouped using ERIC concept-mapping clusters.</p><p><strong>Results: </strong>Of 313 survey respondents, 248 provided responses relevant to implementation. Three barrier themes were shared across consumer and professional/policy stakeholder groups. Theme 1: 'Knowledge gaps, beliefs, and limited readiness to deprescribe' describes gaps in consumers' and clinicians' knowledge, beliefs about medication use and deprescribing, and limited confidence or willingness to engage in deprescribing. Theme 2: 'Communication, hierarchy, or social influences limiting deprescribing' describes communication gaps, entrenched prescribing norms, power imbalances, and social influences that limited shared decision-making. Theme 3: 'System-level structures misaligned with deprescribing practice' describes broader healthcare system barriers, including financial, policy, workforce, organisational, and information-related constraints. Consumers additionally highlighted a lack of person-centred and adaptable approach for deprescribing, while professional/policy stakeholders identified barriers related to medicine formulations and guideline format and usability. Barriers mapped predominantly to the CFIR Inner Setting domain. The highest-ranked implementation strategy was 'Identify and prepare champions', within the 'Develop stakeholder interrelationships' cluster.</p><p><strong>Conclusion: </strong>Deprescribing barriers were largely situated within the Inner Setting domains. Recommended strategies emphasised stakeholder engagement and local champions, supporting locally led, relationship-based implementation approaches. Future work should evaluate the feasibility, acceptability, and effectiveness of these strategies in practice.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-026-02218-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Deprescribing is the planned withdrawal or dose reduction of medicines when harms outweigh benefits or when they are no longer required. Following publication of the Clinical Practice Guideline for Deprescribing in Older People in September 2025, supporting its uptake into routine practice is a critical next step.

Aim: This study aimed to identify implementation strategies, informed by stakeholder-perceived barriers, to support the implementation of deprescribing guidelines.

Method: A qualitative analysis was undertaken of open-text responses collected during the guideline public consultation (24 April-31 May 2025). Inductive thematic analysis identified implementation barriers, which were then deductively mapped to the Consolidated Framework for Implementation Research (CFIR). Relevant CFIR constructs were entered into the CFIR-Expert Recommendations for Implementing Change (ERIC) Matching Tool to generate implementation strategies. Strategies were ranked by cumulative percentage endorsement and grouped using ERIC concept-mapping clusters.

Results: Of 313 survey respondents, 248 provided responses relevant to implementation. Three barrier themes were shared across consumer and professional/policy stakeholder groups. Theme 1: 'Knowledge gaps, beliefs, and limited readiness to deprescribe' describes gaps in consumers' and clinicians' knowledge, beliefs about medication use and deprescribing, and limited confidence or willingness to engage in deprescribing. Theme 2: 'Communication, hierarchy, or social influences limiting deprescribing' describes communication gaps, entrenched prescribing norms, power imbalances, and social influences that limited shared decision-making. Theme 3: 'System-level structures misaligned with deprescribing practice' describes broader healthcare system barriers, including financial, policy, workforce, organisational, and information-related constraints. Consumers additionally highlighted a lack of person-centred and adaptable approach for deprescribing, while professional/policy stakeholders identified barriers related to medicine formulations and guideline format and usability. Barriers mapped predominantly to the CFIR Inner Setting domain. The highest-ranked implementation strategy was 'Identify and prepare champions', within the 'Develop stakeholder interrelationships' cluster.

Conclusion: Deprescribing barriers were largely situated within the Inner Setting domains. Recommended strategies emphasised stakeholder engagement and local champions, supporting locally led, relationship-based implementation approaches. Future work should evaluate the feasibility, acceptability, and effectiveness of these strategies in practice.

使用cfr - eric匹配工具确定描述性临床实践指南实施策略的定性分析:来自消费者和专业利益相关者的观点。
前言:开处方是指当危害大于益处或不再需要药物时有计划的停药或减少剂量。随着2025年9月《老年人处方减少临床实践指南》的发布,支持将其纳入常规实践是关键的下一步。目的:本研究旨在根据利益相关者感知的障碍确定实施策略,以支持描述性指南的实施。方法:对指南公众咨询(2025年4月24日- 5月31日)期间收集的开放文本回复进行定性分析。归纳主题分析确定了实施障碍,然后演绎映射到实施研究综合框架(CFIR)。相关的CFIR结构被输入到CFIR-实施变革专家建议(ERIC)匹配工具中,以生成实施策略。策略按累计认可百分比排序,并使用ERIC概念映射聚类进行分组。结果:在313名调查对象中,248人提供了与实施相关的答复。消费者和专业/政策利益相关者群体分享了三个障碍主题。主题1:“知识差距、信念和解除处方的有限准备”描述了消费者和临床医生在药物使用和解除处方方面的知识差距、信念以及参与解除处方的有限信心或意愿。主题2:“沟通、等级或社会影响限制处方处方”描述了沟通差距、根深蒂固的处方规范、权力不平衡以及限制共同决策的社会影响。主题3:“系统级结构与处方实践不一致”描述了更广泛的医疗保健系统障碍,包括财务、政策、劳动力、组织和信息相关的限制。消费者还强调缺乏以人为本和适应性强的处方方法,而专业/政策利益攸关方则确定了与药物配方和指南格式和可用性有关的障碍。障碍主要映射到CFIR内设置域。在“发展利益相关者相互关系”集群中,排名最高的实施战略是“确定和准备冠军”。结论:处方障碍主要位于内环境域。建议的战略强调利益相关者的参与和地方拥护者,支持地方领导的、基于关系的实施方法。未来的工作应该评估这些策略在实践中的可行性、可接受性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
8.30%
发文量
131
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences. IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy. IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor. International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy . Until 2010 the journal was called Pharmacy World & Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书